In this video, Claudio Soto—CSO of Amprion—explains the neuroscience behind Amprion’s breakthrough Prion Early Detection Science relating to Alzheimer’s, Parkinson’s, and other neurodegenerative disease. Find out what causes Alzheimer’s and Parkinson’s, and why early detection prior to the start of any clinical symptoms have been so challenging. Prion early detection science at the molecular level gives us 20/20 vision to track the biomarkers that cause, and drive, the progression of these neurodegenerative disease.
Want to learn more about brain health? SUBSCRIBE to this channel for regular updates.
Why Early Prion Detection Science is Key to Finding a Cure?
The key problem is that the brain is a tissue that doesn’t recover very well. When it’s damaged, it’s very difficult to restore function. Alzheimer’s and Parkinson’s are caused by misfolded proteins in the brain that produce toxicity, kill neurons and destroy the brain. In Alzheimer’s there are two different proteins that misfold and aggregate, what we call Amyloid Abeta protein and the Tau protein, and in Parkinson’s disease there is another protein called Alpha Synuclein.
Today the main problem for clinical diagnosis is that the diagnosis is based on symptoms and symptoms come after a large part of the brain is destroyed. So the misfolded proteins although accumulate in the brain, it’s known that they travel everywhere in the body, through the blood, present in many different tissues, and even secreted in urine, but the amount is so small that it’s really impossible to detect by any standard techniques. The main challenge to track this process is that these misfolded proteins accumulate in large amount only in the brain. So the brain is a difficult tissue to access.
You cannot do a brain biopsy for a diagnosis. So the amount of material circulating in biological fluids is very, very small. Especially in the beginning of the process. At the moment, they’re invisible by any other technique, we can’t see them. What Amprion is doing is to amplify this process, as it happens in the disease, but instead of doing it as it happens in disease in years or decades, we do it in a few hours in the laboratory. We can perform prion detection with extremely high efficiency, sensitivity and specificity misfolded proteins that accumulate in the brain and amplify them so that we can see them when they’re invisible.
The dream is to have a technology that can be used for everybody when they approach 40’s or 50’s. We can tell people, “Oh look, your brain is starting to get damaged, and you are on the way to develop one disease or another.” And detect this process before it produces any damage in the brain, before it produces any clinical symptoms. So that one day we can say there was a time in which a lot of people developed Alzheimer’s disease, today, nobody really has the disease because we detect early and we intervene with a safe treatment to eliminate the problem.
We want to help physicians to diagnose patients and we’re going to help them to diagnose as early as possible so that they can apply these lifestyle changes. The other way that we can help pharmaceutical companies is that we can help them to engage the right patients into the clinical trials, and we can help them to monitor the success of the trial by our technology. Amprion is all about helping people with these devastating neurodegenerative diseases. These are diseases that destroy the quality of life of people. And we’re trying to develop technology that can help physicians and drug companies to diagnose people and also develop prion early detection science technologies for Alzheimer’s disease, Parkinson’s disease, and other brain-related disorders.
Related Posts on Prion Early Detection Science:
- The Amprion Story | Early Detection for Alzheimer’s & Parkinson’s
- The Origin Story | Early Detection for Alzheimer’s and Parkinson’s
- Simple Test to Detect Variant Creutzfeldt-Jakob Disease [vCJD]
- Accurate CJD Diagnosis & Prevention of Disease Transmission